The Global Prevalence of Daptomycin, Tigecycline, and Linezolid-Resistant and Strains From Human Clinical Samples: A Systematic Review and Meta-Analysis

Overview

Journal Front Med (Lausanne)

Specialty General Medicine

Date 2021 Sep 27

PMID 34568377

Citations 23

Authors

Masoud Dadashi

Parastoo Sharifian

Nazila Bostanshirin

Bahareh Hajikhani

Narjess Bostanghadiri

Nafiseh Khosravi-Dehaghi

Alex van Belkum

Davood Darban-Sarokhalil

Affiliations

Soon will be listed here.

Abstract

The predominant species of the () and () cause great variety of infections. Therefore, the expansion of antimicrobial resistance in the is one of the most important global concerns. This study was conducted to investigate the prevalence of resistance to linezolid, tigecycline, and daptomycin among enterococcal strains isolated from human clinical specimens worldwide. Several databases including Web of Science, EMBASE, and Medline ( PubMed), were carefully searched and reviewed for original research articles available in databases and published between 2000 and 2020. A total of 114 studies worldwide that address and resistance to linezolid, tigecycline, and daptomycin were analyzed by STATA software. The overall prevalence of antibiotic-resistant and was reported to be 0.9 and 0.6%, respectively. and were more resistant to the linezolid (2.2%) and daptomycin (9%), respectively. The prevalence of tigecyline-resistant (1%) strains was higher than strains (0.3%). Accordingly, the prevalence of linezolid-resistant was higher in Asia (2.8%), while linezolid-resistant was higher in the America (3.4%). Regarding tigecycline-resistance, a higher prevalence of (0.4%) and (3.9%) was reported in Europe. In conclusion, this meta-analysis shows that there is an emerging resistance in strains. Despite the rising resistance of enterococci to antibiotics, our results demonstrate that tigecycline, daptomycin, and linezolid can still be used for the treatment of enterococcal infections worldwide.

Citing Articles

A Novel Ammonium Carboxylate Salt of Undecylenic Acid for the Topical Treatment of Gram-Positive and Antibiotic-Resistant Skin Infections.

Mayfosh A, Rau T Exp Dermatol. 2025; 34(3):e70075.

PMID: 40062430 PMC: 11891955. DOI: 10.1111/exd.70075.

First Detection and Genomic Characterization of Linezolid-Resistant Clinical Isolates in Bulgaria.

Strateva T, Hristova P, Stoeva T, Hitkova H, Peykov S Microorganisms. 2025; 13(1).

PMID: 39858963 PMC: 11767806. DOI: 10.3390/microorganisms13010195.

Vancomycin-Resistant Enterococci: Current Understandings of Resistance in Relation to Transmission and Preventive Strategies.

Marekovic I, Markanovic M, Lesin J, Coric M Pathogens. 2024; 13(11).

PMID: 39599519 PMC: 11597547. DOI: 10.3390/pathogens13110966.

Trivalent immunization with metal-binding proteins confers protection against enterococci in a mouse infection model.

Lam L, Sedra A, Kajfasz J, Berges A, Saengpet I, Adams G FEMS Microbes. 2024; 5:xtae031.

PMID: 39524556 PMC: 11549557. DOI: 10.1093/femsmc/xtae031.

Emergence of lineage ST150 and linezolid resistance in : a molecular epidemiology study of UTIs in Tehran, Iran.

Seyedolmohadesin M, Kouhzad M, Gotz F, Ashkani M, Aminzadeh S, Bostanghadiri N Front Microbiol. 2024; 15:1464691.

PMID: 39469459 PMC: 11514486. DOI: 10.3389/fmicb.2024.1464691.

References

Korpela K, Blakstad E, Moltu S, Strommen K, Nakstad B, Ronnestad A . Intestinal microbiota development and gestational age in preterm neonates. Sci Rep. 2018; 8(1):2453. PMC: 5802739. DOI: 10.1038/s41598-018-20827-x. View

Chen Q, Yin D, Li P, Guo Y, Ming D, Lin Y . First Report and Co-harboring Linezolid-Resistant in China. Infect Drug Resist. 2020; 13:3919-3922. PMC: 7646505. DOI: 10.2147/IDR.S270701. View

Hoban D, Reinert R, Bouchillon S, Dowzicky M . Global in vitro activity of tigecycline and comparator agents: Tigecycline Evaluation and Surveillance Trial 2004-2013. Ann Clin Microbiol Antimicrob. 2015; 14:27. PMC: 4489028. DOI: 10.1186/s12941-015-0085-1. View

Rodriguez-Noriega E, Hernandez-Morfin N, Garza-Gonzalez E, Bocanegra-Ibarias P, Flores-Trevino S, Esparza-Ahumada S . Risk factors and outcome associated with the acquisition of linezolid-resistant Enterococcus faecalis. J Glob Antimicrob Resist. 2020; 21:405-409. DOI: 10.1016/j.jgar.2020.01.010. View

Campeau S, Schuetz A, Kohner P, Arias C, Hemarajata P, Bard J . Variability of Daptomycin MIC Values for Enterococcus faecium When Measured by Reference Broth Microdilution and Gradient Diffusion Tests. Antimicrob Agents Chemother. 2018; 62(9). PMC: 6125562. DOI: 10.1128/AAC.00745-18. View

Leong H, Kurup A, Tan M, Kwa A, Liau K, Wilcox M . Management of complicated skin and soft tissue infections with a special focus on the role of newer antibiotics. Infect Drug Resist. 2018; 11:1959-1974. PMC: 6208867. DOI: 10.2147/IDR.S172366. View

Turnidge J, Kahlmeter G, Canton R, MacGowan A, Giske C . Daptomycin in the treatment of enterococcal bloodstream infections and endocarditis: a EUCAST position paper. Clin Microbiol Infect. 2020; 26(8):1039-1043. DOI: 10.1016/j.cmi.2020.04.027. View

Liu Y, Wang Y, Schwarz S, Li Y, Shen Z, Zhang Q . Transferable multiresistance plasmids carrying cfr in Enterococcus spp. from swine and farm environment. Antimicrob Agents Chemother. 2012; 57(1):42-8. PMC: 3535926. DOI: 10.1128/AAC.01605-12. View

Munita J, Panesso D, Diaz L, Tran T, Reyes J, Wanger A . Correlation between mutations in liaFSR of Enterococcus faecium and MIC of daptomycin: revisiting daptomycin breakpoints. Antimicrob Agents Chemother. 2012; 56(8):4354-9. PMC: 3421602. DOI: 10.1128/AAC.00509-12. View

10.

Orababa O, Soriwei J, Akinsuyi S, Essiet U, Solesi O . A systematic review and meta-analysis on the prevalence of vancomycin-resistant enterococci (VRE) among Nigerians. Porto Biomed J. 2021; 6(1):e125. PMC: 8055482. DOI: 10.1097/j.pbj.0000000000000125. View

11.

Emaneini M, Hosseinkhani F, Jabalameli F, Nasiri M, Dadashi M, Pouriran R . Prevalence of vancomycin-resistant Enterococcus in Iran: a systematic review and meta-analysis. Eur J Clin Microbiol Infect Dis. 2016; 35(9):1387-92. DOI: 10.1007/s10096-016-2702-0. View

12.

Mantel N, Haenszel W . Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959; 22(4):719-48. View

13.

DerSimonian R, Laird N . Meta-analysis in clinical trials. Control Clin Trials. 1986; 7(3):177-88. DOI: 10.1016/0197-2456(86)90046-2. View

14.

Silverman J, Oliver N, Andrew T, Li T . Resistance studies with daptomycin. Antimicrob Agents Chemother. 2001; 45(6):1799-802. PMC: 90548. DOI: 10.1128/AAC.45.6.1799-1802.2001. View

15.

Stefani S, Bongiorno D, Mongelli G, Campanile F . Linezolid Resistance in Staphylococci. Pharmaceuticals (Basel). 2016; 3(7):1988-2006. PMC: 4036669. DOI: 10.3390/ph3071988. View

16.

Zasowski E, Trinh T, Claeys K, Casapao A, Sabagha N, Lagnf A . Multicenter Observational Study of Ceftaroline Fosamil for Methicillin-Resistant Staphylococcus aureus Bloodstream Infections. Antimicrob Agents Chemother. 2016; 61(2). PMC: 5278749. DOI: 10.1128/AAC.02015-16. View

17.

Mendes R, Castanheira M, Farrell D, Flamm R, Sader H, Jones R . Longitudinal (2001-14) analysis of enterococci and VRE causing invasive infections in European and US hospitals, including a contemporary (2010-13) analysis of oritavancin in vitro potency. J Antimicrob Chemother. 2016; 71(12):3453-3458. DOI: 10.1093/jac/dkw319. View

18.

Higgins J, Thompson S . Quantifying heterogeneity in a meta-analysis. Stat Med. 2002; 21(11):1539-58. DOI: 10.1002/sim.1186. View

19.

Wang J, Hsueh P . Therapeutic options for infections due to vancomycin-resistant enterococci. Expert Opin Pharmacother. 2009; 10(5):785-96. DOI: 10.1517/14656560902811811. View

20.

van Harten R, Willems R, Martin N, Hendrickx A . Multidrug-Resistant Enterococcal Infections: New Compounds, Novel Antimicrobial Therapies?. Trends Microbiol. 2017; 25(6):467-479. DOI: 10.1016/j.tim.2017.01.004. View